Cell Signaling | Protein Chemistry & Proteomics | Medical Genetics | Immunomodulation | Control of Gene Expression | Lymphomas & Myelomas
The anti-CD20 Mab R603 induces PTEN and RKIP expression in B-NHL cells: role in inhibition of constitutively activated Akt and NF-κB survival anti-apoptotic pathways
Loredana Militello, Stavroula Baritaki, Eriko Suzuki, Mario I. Vega, Margarita Salcedo, Benjamin Bonavida*
*Corresponding author: Benjamin Bonavida
Microbiology, Immunology & Molecular Genetics, University of CA, Los Angeles, Los Angeles, CA, USA
F1000Posters 2010, 1: 85 (poster) [ENGLISH]
Poster [463.93 KB]
Presented at
51st American Society of Hematology Annual Meeting 2009,
5 - 8 Dec 2009, 1970
The monoclonal anti-CD20 R603 was shown to inhibit the PI3K/Akt survival pathway through the induction of PTEN.
We have reported previously that anti-CD20 rituximab inhibits the PI3K/Akt pathway in B-NHL cell lines. In this study, we show that the mechanism by which the PI3K/Akt pathway is inhibited was due, in part, through the induction of the inhibitor PTEN.
Methods used included tumor cell lines, analysis of proliferation, gene products by western, and apoptosis by caspase-3 activation and analysis of apoptotic pathways.
This study reports a novel mechanism of anti-CD20 therapeutic efficacy in B-NHL and B-mediated diseases by identifying a novel target, PTEN, which is underexpressed in the tumors. The study also suggests that inducers of PTEN can mimic anti-CD20 monoclonal antibody and further they can be therapeutic in resistant variants unresponsive to CD20.
No relevant conflicts of interest declared.
Please note that most posters on this site present work that is preliminary in nature and has not been peer reviewed.
This poster is open access subject to the CC BY-NC Creative Commons 3.0 License
